The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
A very welcome and positive update. It's still 'jam tomorrow' but the shelves are filling up. Gla
WTP You are quite right the wording is much more positive. I suspect the new chairman had some input into that.
Shame He wasn't around to announce the MABs deal
I also believe for once Scancell have made the right decision to shelf the Covidity program.
Forget about the need for a next generation Vax, Forget about the potential of a another Coronavirus epidemic This is a business decision ‘Follow the money’ and at the moment the money isn’t with a Covid Vax.
It may well come later but Scancell are developing a World beating Cancer Vac, get it right and it’s worth £Billions thus IMO all recourses should be concentrated on this . GLA
Quick observation - What a fantastic BB this has become
Thank you & well done to all current contributors
GLA
Yesterday highlighted the disparity between SP and value on the AIM market. In recent weeks we’ve had several blockbuster RNS’s yet only a muted SP rise due to share liquidity provided (we think) by Calculas exiting or part exiting their position.
The regular 200,000 sells of recent weeks appear to have stopped and Hey Presto on similar volume the SP is up 10%
Hopefully the SP can rise to somewhere near value before the next news arrives GLA
'next scan Nov 30th' and Lindy states an update before year end
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: "This is an encouraging milestone for the Company, showing that the higher dose of Modi-1 is generating immune responses that may be having an impact on tumour growth. We are encouraged that there were no safety concerns in Cohort 2, allowing us to proceed with the monotherapy expansion and into Cohort 3 in combination with checkpoint inhibitors, and look forward to announcing further safety and immunogenicity data in H2 2022."
'directingas, excellent post.
Open question to all..........................Why are we at 16.5/17p?'
Unfortunatly the SP is dictated by the traders irrelavent of the news, If it goes down 10% they buy, up 10% sell, Secondly Calculas or whoever it is selling hasn't been helpfull.
However we are entering a new phase , I don't think the news from the last 7 days has sunk in. larger buyers will emerge and the market will do what the market does, 50p by Chrishmas would be nice
Putting a value on Scancell has become alot easier since last weeks Genmab deal. Genmab value a single mab from Scancells Glymab platform at around £0.5billion plus royalties
Scancell already have 5 mabs in early development with the capability of producing many more. All things being equal if we estimate another future 5 then Genmab value the platform at a potential £5billion
It is only potential so what value should we put on potential I'd estimate 10% thus £500million (approx 50p per share) for the Glymab platform alone
The immunobody and moditope platforms are much further advanced, semi proven thus less risk but higher potentials .
Figures are figures , all good fun. GLA
Whilst the market sleeps Scancell have been on the boil
Within 7 days we've got news of
a deal with Genmad potentially worth £0.5billion +
End of year report highlighting progress across all platforms (even with a small cash burn)
Moditope progression with potential tumour shrinkage
GLA
WOW
Well done to all the team at Scancell
Crumbs, Good thinking, the upfront payment has to be declared at some point even if it's end of year accounts so why not now, Perhaps another deal is imminent . GLA
I’d have to agree Time is the major factor defining the current SP. Can you imagine the SP now if Scancell had achieved all that we had and it was just 2015
Enthusiasm declines with time not the potential..
When I was an apprentice I remember one of the engineers sending me to the store for a long wait. I was fortunate the storeman informed me waits were out of stock. Maybe Scancell had brought them all !
more patience required , we are getting closer to the end GLA
If we assume the decision to ditch Ichor is due to Data from the Covidy trial this will have been over some time. Changing the SCIB1 trial to use Pharmajet delivery would of probably taken some months in itself. Thus early Data would have been good perhaps January and backed up by more recent Data enabling Scancell to confirm their decision.
I’m Looking forward to a ‘BOOM’ Covidy update, Maybe next week !
GLA.
For years we’ve been informed that the Ichor delivery device gives an enhanced medical response. The Ichor device has been a chain & ball for Scancell. It requires specific training to use, It has some albeit minor side effects, it frightens potential patients with the unknown and has held back US trial approval.
This SCIB1 phase 2 trial has been painfully slow to recruit patients thus Scancell have now abandoned the Ichor device for the Pharmajet needle free injection.
The questions then are
Is this a gamble to get patients enrolled on the trial that to be honest had been going nowhere..?
Was the amazing results from phase 1 in spite of Ichor rather than enhanced by Ichor ?
Have we received fantastic data from the Covidity trial deeming the Ichor device unnecessary ?
Like others have already suggested I’d suspect the later.
If RG is the new cheif business officer it's highly unlikely he would come out of retirement for a full time post. More likely He's stepped in short term to get a specific task across the line. Interesting developement IMO
LTH will remember ( 2012 i think) it was RG that was selling the company for attractive multiples of the current share price (36p at the time)
Maybe 2nd time lucky
This is a good site for anybody interested in the figures https://www.worldometers.info/coronavirus/ Tests per million is interesting and probably no coincidence that country's that test the most have the highest Covid death fifures. Few countries test more than the UK, currently 6.1 test's per million against 2.8 for France and only 0.24 for Thailand .
Nice posts RR and Ipad
It was suggested that 1 in 15 UK citizens had covid over the Xmas hols so by laws of average 1 in 15 deaths will have tested positive for Covid. In reality this will be higher since you are more likely to catch Covid around a hospital setting and indeed when your immune system is low. Figures are figures, make of them what you will but making comparisons to other countries who's reporting is different isn't possible. GLA
I see they have updated In the small print ' Scancell has initiated a Phase 1 clinical trial known as COVIDITY in October 2021.'
Alas no update on Moditope GLA
Thanks for your thoughts,
So assuming vaccine ready to go, 'administer ' ready to go ( The needle free delivery must of had approval given the messing with the Ichor device approval we've previously witnessed)
Then surely there shouldn't be long to wait
GLA